Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2023 16:30 ET | Source: ACELYRIN, INC.

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca PLC brings more than 30 years of strategic expertise in human resources, business operations, and corporate...
November 27, 2023 16:30 ET | Source: ACELYRIN, INC.

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
November 07, 2023 16:05 ET | Source: ACELYRIN, INC.

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease...
November 06, 2023 07:00 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer

Expands capacity for multi-asset manufacturing with highly accomplished supply chain, manufacturing and quality control leader bringing more than 25 years of biopharmaceutical experience across...
October 31, 2023 16:30 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023

LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
October 03, 2023 07:00 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

Veteran drug developer and prior CMO from Novartis AG gene therapies brings decades of clinical experience including long tenure as Global Lead for secukinumab, which he advanced from early...
September 11, 2023 16:05 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last...
September 06, 2023 07:00 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

LOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage biopharma company focused on accelerating the development and delivery of transformative medicines in...
August 14, 2023 16:05 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the...
August 07, 2023 16:30 ET | Source: Acelyrin, Inc.

ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023

LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...